Open an account

Unicycive Therapeutics

UNCY · NASDAQ

$3.80+$0.29 (+8.26%)TodayMarket closed ·
Prev close $3.51

About UNCY

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The company is headquartered in Los Altos, California and currently employs 21 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Employees
21
Headquarters
Los Altos, California
Listed
Jun 17, 2021
Sector
Health Care
Industry
Biotechnology
Website
unicycive.com

UNCY key statistics

Market cap
105.85M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
976.10K
Volume
1.21M
Open price
$3.53
High today
$3.87
Low today
$3.52
52 Week high
$8.74
52 Week low
$3.35

Unicycive Therapeutics (UNCY) at a glance

Unicycive Therapeutics (UNCY) last traded at $3.80, with a market cap of 105.85M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.52 and $3.87. The current price is 8.0% above the day's low and 1.8% below its high.

Volume so far is 1.21M shares, above the average of 976.10K shares a day.

Over the past year Unicycive Therapeutics has ranged from $3.35 to $8.74, and now sits 8% of the way up that range.

Unicycive Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.06 per share against an estimate of -$0.343.

The average analyst price target is $28.97, 662.3% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 12 analystsAvg $28.97
Low
$13.13
Now
$3.80
High
$44.10

UNCY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 56.0% on average.

  1. Q3 FY24: reported -$0.50 per share against an estimate of -$1.55
  2. Q4 FY24: reported -$2.60 per share against an estimate of -$0.918
  3. Q1 FY25: reported -$0.50 per share against an estimate of -$1.16
  4. Q2 FY25: reported -$0.52 per share against an estimate of -$0.7548
  5. Q3 FY25: reported -$0.33 per share against an estimate of -$0.5678
  6. Q4 FY25: reported -$0.819 per share against an estimate of -$0.4828
  7. Q1 FY26: reported -$0.54 per share against an estimate of -$0.4852
  8. Q2 FY26: reported -$0.06 per share against an estimate of -$0.343

UNCY news

  • Press releaseGlobe Newswire

    Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role

  • Press releasePRNewswire

    INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Unicycive Therapeutics, Inc. to Contact Law Firm

  • Press releaseGlobe Newswire

    Deadline Alert: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds

  • Press releaseNewsfile

    Kaplan Fox Encourages Unicycive Therapeutics, Inc. (UNCY) Investors Seeking Recovery to Contact the Firm Before November 2, 2026

  • Press releaseNewsfile

    Kaplan Fox Advises Investors of Unicycive Therapeutics, Inc. (UNCY) of an Upcoming Securities Class Action Deadline on November 2, 2026

  • Press releasePRNewswire

    SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY

  • Press releaseGlobe Newswire

    Unicycive Therapeutics, Inc. Class Action Reminder - Robbins LLP Encourages UNCY Investors to Contact the Firm About Their Rights

  • Press releaseGlobe Newswire

    Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Similar companies

Companies in the same industry as Unicycive Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.